Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Inclusion Criteria:

Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)
Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 cycles of chemotherapy
Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1

Exclusion Criteria:

Small cell lung cancer (SCLC) or mixed SCLC and NSCLC
Central nervous system (CNS) metastases
Malignancy other than NSCLC
Palliative radiotherapy for bone lesions inside the thorax
Prior radiotherapy of bone marrow
Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
Life expectancy < 6 months
Woman of child-bearing potential who is pregnant or is breast feeding or who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment
Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment
Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products
Other inclusion/exclusion criteria may apply